Cardiome Pharma Corp.  (CRME) Trade Now »     Rate CRME  -  Discuss CRME  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

CRME: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Updated FDA, Clinical Trial Calendars: CRME, MRK, LLY, PRX CRME

73%

-1.71% in 232 days Below is a summary of updates to the BioMedReports.com database of 242 entries included in the FDA and Clinical Trial Calendars .   http://biomedreports.com/fda-calendar.html   <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 115 entries through 4/9/09. The FDA Calendar includes the following information: company name, ticker, decision ... Continue reading »

From the Blogosphere

A Short Trade on Pending FDA Decisions

73%

The accompanying table presents an updated calendar of expected FDA decisions along with the trailing 52-week stock price change for each company. In addition to higher volatility, the companies with pending FDA decisions tend to perform worse as a group compared to benchmark ETFs in the past two years that I have tracked this index – making the index an ideal candidate for a new short ETF to provide investors with inverse exposure to this underperformance. Some likely near-term movers on the FDA's decision date calendar for 70 different items (click to enlarge, left) include Cypress... Continue reading »

FDA Calendar: Cardiome, Momenta, Discovery Labs, Introgen CRME

-65.82% in 477 days click to enlarge Continue reading »

Thursday's Upgrades and Downgrades

2 %

<> Upgrades QLogic (QLGC)- Pacific Growth Equities Neutral » Buy Massey Energy (MEE)- Caris & Company Above Average » Buy PF Chang's (PFCB)- Wedbush Morgan Sell » Hold Scotts Miracle-Gro (SMG)- BMO Capital Markets Underperform » Market Perform Walgreen (WAG)- Credit Suisse Neutral » Outperform SW Energy (SWN)- Sun Trust Rbsn Humphrey Neutral » Buy Ultra Petroleum (UPL)- Sun Trust Rbsn Humphrey Neutral » Buy American Eagle (AEO)- Needham Underperform » Hold Brigham Exploration (BEXP)- JP Morgan Underweight » Overweight Concho Resources (CXO)- Sun T... Continue reading »

Thursday's Upgrades and Downgrades

<> Upgrades QLogic (QLGC)- Pacific Growth Equities Neutral » Buy Massey Energy (MEE)- Caris & Company Above Average » Buy PF Chang's (PFCB)- Wedbush Morgan Sell » Hold Scotts Miracle-Gro (SMG)- BMO Capital Markets Underperform » Market Perform Walgreen (WAG)- Credit Suisse Neutral » Outperform SW Energy (SWN)- Sun Trust Rbsn Humphrey Neutral » Buy Ultra Petroleum (UPL)- Sun Trust Rbsn Humphrey Neutral » Buy American Eagle (AEO)- Needham Underperform » Hold Brigham Exploration (BEXP)- JP Morgan Underweight » Overweight Concho Resources (CXO)- Sun T... Continue reading »

Pre-Open Movers 7/14: Fannie (FNM), Freddie (FRE) Up On U.S. Back-Stop Plan; Republic Services (RSG) Up on Waste Management Offer

StreetInsider.com Pre-Open Movers: <>IndyMac Bank (NYSE: IMB) 35% LOWER; IndyMac Shut Down Due To Bank Run, FDIC Takes Over Cardiome Pharma Corp. (NASDAQ: CRME) 30% HIGHER; announced positive clinical results from its 90-day Phase 2b study of vernakalant (oral). Cardiome Pharma said the final analysis demonstrated statistically significant efficacy for the patient group receiving 500mg b.i.d. of vernakalant (oral) as compared to placebo. The safety data from the final analysis also shows that vernakalant (oral) was well-tolerated in the atrial fibrillation population studied. Fannie Mae (NYSE:... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.